Form 4 for TVTX Travere Therapeutics, Inc.

Accepted 2023-02-02 00:00:00 ET · period of report 2023-01-31 · accession 0001209191-23-006436 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-02-02	2023-01-31	TVTX	REED ELIZABETH E	SVP, GC, Corp. Sec	A - Grant	$0.00	+20.2K	60.0K	+51%	$0
D	2023-02-02	2023-02-01	TVTX	REED ELIZABETH E	SVP, GC, Corp. Sec	S - Sale	$22.25	-2,590	57.4K	-4%	-$57.6K
DM	2023-02-02	2023-01-31	TVTX	REED ELIZABETH E	SVP, GC, Corp. Sec	A - Grant	$0.00	+61.2K	6,750	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-01-31	A	A	20,250	$0.00	60,026	D	—	—
2	Common	Common Stock	2023-02-01	S	D	2,590	$22.25	57,436	D	—	—
3	Derivative	Employee stock option (right to buy)	2023-01-31	A	A	54,500	$0.00	54,500	D	$22.40 · — to 2033-01-30	54,500 Common Stock	(F3) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
4	Derivative	Performance-based restricted stock units	2023-01-31	A	A	6,750	$0.00	6,750	D	— · — to —	6,750 Common Stock	(F1) Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. (F4) This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.